Purpose Important drugs in the treatment of childhood acute lymphoblastic leukaemia (ALL) are 6-mercaptopurine (6-MP) and methotrexate (MTX). Thiopurine methyltransferase (TPMT) is a polymorphic enzyme causing variability in 6-MP response and toxicity. The aim of this study was to investigate the fluctuation in TPMT enzyme activity over time and the effect of high-dose MTX infusions on TPMT enzyme activity and 6-MP metabolites in paediatric ALL patients. Methods Fifty-three children with ALL treated according to the NOPHO-ALL 2000 protocol were included in the study. TPMT enzyme activity was measured at six different times starting from diagnosis until after the end of maintenance treatment. TPMT and 6-MP metabolites were measured before the initiation of high-dose MTX (HD-MTX) infusions and at 66 h post-infusion. The interaction between MTX and TPMT was investigated in vitro using recombinant TPMT protein and a leukaemic cell line. Results Forty percent of TPMT wild-type individuals had deceptively low TPMT enzyme activity according to genotype at the time of diagnosis. TPMT activity had decreased significantly 66 h after the start of HD-MTX infusions (−9.2 %; p=0.013). MTX bound to recombinant TPMT protein severely inhibiting TPMT enzyme activity (remaining activity 16 %). Conclusions Our results show that TPMT genotyping should be performed in children with ALL, since 40 % of the children in our study who carried the wild-type TPMT gene were at risk of initial underdosing of 6-MP in cases where only TPMT enzyme activity was determined. MTX inhibits the TPMT enzyme activity after HD-MTX infusions due to protein binding.
Introduction
In Nordic countries, children diagnosed with acute lymphoblastic leukaemia (ALL) are managed using a common treatment protocol where stratification into risk groups based on prognostic factors determines the exact treatment schedule. Of the about 180 children annually diagnosed in the Nordic Countries, event-free survival is approximately 80 % [1] . Treatment-related toxicity can be life-threatening and is the primary cause of less intensive, interrupted or even discontinued maintenance chemotherapy, all of which can lead to an increased risk for relapse [2] . The antimetabolite 6-mercaptopurine (6-MP) is an important component of ALL treatment and is partly metabolised by the enzyme thiopurine methyltransferase (TPMT).
TPMT activity varies within populations as a result of a common genetic polymorphism [3] . Individuals carrying two non-functional TPMT alleles (1 out of 300 in Caucasian populations) are at an increased risk for severe side effects if treated with conventional thiopurine doses [4, 5] . Approximately 9 % of the Caucasian population are TPMT heterozygous, carrying one non-functional allele. Studies have shown that these individuals also benefit from dose reduction [4] . Since the implementation of the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-2000 protocol, it is mandatory to determine TPMT status of a patient before the start of 6-MP treatment.
In the NOPHO ALL-2000 protocol, methotrexate (MTX) is given from the time of diagnosis (usually as intrathecal injections) and is used as an oral treatment during a maintenance treatment block, as well as in high-dose intravenous infusions starting in the consolidation therapy. For example, children treated according to the standard risk protocol receive a high-dose MTX (HD-MTX) infusion in a dose of 5 g/m 2 during a 24-h period and calcium folinate rescue (15 mg/m 2 ) beginning 42 h after the start of the MTX infusion. In the maintenance therapy, MTX is given orally once weekly (target dose 20 mg/m 2 /kg body weight) and 6-MP orally every evening from 17 weeks until 2-2.5 years after diagnosis. The administration of 6-MP and MTX affect S-adenosyl L-methionine (SAM) metabolism in the cell by inhibiting the folate-dependent regeneration of S-adenosyl homocysteine (SAH). Inhibition of dihydrofolate reductase by MTX (which thus inhibits the formation of tetrahydrofolate) increases the plasma concentration of SAH [6] . Both 6-MP and MTX inhibit de novo purine synthesis (DNPS), and the combination of 6-MP and MTX leads to a pronounced inhibition of DNPS in vivo compared to that by 6-MP or MTX alone [7] . The interaction between the drugs is complex, and the cellular response to the drugs is prompt. In addition, genetic polymorphisms in genes encoding transporters (such as the reduced folate carrier) and enzymes involved in MTX uptake and metabolism affect the treatment outcomes and toxicity [8] .
Given that 6-MP and MTX are important drugs in the treatment of childhood ALL and that TPMT is a polymorphic enzyme causing variability in 6-MP response and toxicity, we have investigated the fluctuation in TPMT enzyme activity from the time of diagnosis until after the end of maintenance treatment. We have also examined the effect of HD-MTX infusions on TPMT enzyme activity and 6-MP metabolites. Recombinant protein was used to investigate the binding of MTX to the TPMT protein, and a leukaemic cell line was used to study the effects of HD-MTX infusions on TPMT enzyme activity in vitro.
Methods

Patients
Fifty-three children who were starting their treatment according to the NOPHO ALL-2000 protocol for ALL were enrolled in this study. According to the protocol, patients were placed into risk groups depending on pre-therapeutic factors and treated accordingly. The classification criteria of the risk groups are listed in Table 1 TPMT genotyping DNA was isolated from whole blood using the QIAamp DNA mini kit (Qiagen, Germany, Hilden). Three common variants in the TPMT gene (238G > C, 460G > A and 719A > G) were searched for by pyrosequencing as previously described [9] .
TPMT enzyme activity assay in red blood cells
The TPMT enzyme activity was measured as previously described in Pettersson et al. (2002) through determination of the formation of 6-methylmercaptopurine (6-meMP) from 6-MP using radio-labelled SAM as the methyl donor. Product formation was measured using a scintillation counter. One unit of enzyme activity represents the formation of 1 nmol of 6-meMP per millilitre of packed red blood cells (pRBC) per hour of incubation. Cut-off points of 9.0 and 2.5 U/ml pRBC were used to distinguish high from intermediate enzyme activity and intermediate from low enzyme activity, respectively [10, 11] .
Determination of TGN and meTIMP
The concentrations of TGN and meTIMP were determined in washed RBCs using high-performance liquid chromatography (HPLC) as described previously [11] . Results were expressed as pmol/8 × 10 8 RBC. Normalised metabolite levels were calculated by dividing the measured metabolite levels with daily 6-MP dose.
In vitro incubations of the cell line MOLT4 and MTX MOLT4 cells, a human T-lymphoblastic cell line from the American Tissue Culture Collection (ATCC, Rockville, MD), were cultured in RPMI1640 supplemented with 10 % foetal calf serum (Gibco, Paisley UK) and subcultivated twice every week. Methotrexate (Sigma-Aldrich St Louis, MO) was dissolved in 50 mM NaOH and added to the cell culture (20 ml of 0.3×10 6 cells/ml) which gave a final concentration of 90 μM; this suspension was incubated for 24, 48 and 72 h at 37°C in an atmosphere of 5 % CO 2 . Cells incubated only with NaOH at the final concentrations, as for the MTX-treated cells (0.3 %), were used as controls (control vehicle, CV). To check that the CV did not significantly influence the TPMT enzyme activity, untreated cells were also included in each experiment. All experiments were performed in triplicate, and at each time point two culture flasks with the same treatment were harvested. At the time of harvesting, 3.5×10 6 cells were transferred to a 50 ml-tube. The incubation was ended by removing the medium after centrifugation at 500 g for 10 min. The cell pellets were washed in 10 ml phosphate buffered saline (PBS), centrifuged, re-suspended in 1 ml PBS and centrifuged again. The cell pellets were stored in −80°C until protein extraction.
At the time of protein extraction, the pellets were placed on ice and sonicated four times for 5 s each time in 500 μl extraction buffer [50 mM Tris-HCl (pH 7.6), 2 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride, TPMT enzyme activity in MOLT4 cells
The enzyme activity of TPMT in MOLT4 cells was determined by measuring the rate of formation of 6-methylmercaptopurine from 6-MP using 14 C-labeled SAM as the methyl group donor [12] . A 200-μg sample of total cellular protein was incubated in duplicate for 2 h at 37°C in 400 μl of 47 mmol/l potassium phosphate buffer (pH 7.5) supplemented with 3 mmol/l 6-MP, 0.4 mmol/l DTT, 0.2 mmol/l allopurinol and a mixture of SAM and 14 Clabeled SAM (GE Healthcare, Uppsala, Sweden) giving a total SAM concentration of 10 μM. After 2 h, all reactions were stopped by the addition of 2 ml of acetonitrile. The organic phase was collected, evaporated and then reconstituted in 20 mmol/l KH 2 PO 4 (pH 2.7) to a total volume of 100 μl. A 50-μl sample was analysed by HPLC using a Purospher STAR, RP18 (3 μm, 55×4 mm) column maintained at 30°C (MERCK, Darmstadt, Germany) with a Gemini C18 4×2-mm precolumn from Phenomenex (Torrance, CA). The mobile phase consisted of 20 mmol/l KH 2 PO 4 (pH 2.7) with 15 % methanol (v/v). The ultraviolet (UV) signal at 290 nm was used to determine the retention time of meMP, and the signal of a scintillation detector was used to determine the enzyme activity. The enzyme activity TPMT in MTX-treated cells was expressed as the percentage of CV-treated cells.
In vitro studies using recombinant TPMT protein
Construction of TPMT variants
Human wild-type TPMT, encoding residues 1-245, was cloned into vector pET28-Lic, generously provided by Structural Genomics Consortium (SGC; Toronto, Canada) and was transformed into the Escherichia coli strain BL21-Codon plus (DE3)-RIL (Novagen, Gibbstown, NJ) for large-scale expression.
Large-scale expression and purification
Escherichia coli BL21-Codon plus (DE3)-RIL, transformed with the plasmid pET28-Lic, was expressed in LB medium and cultivated at 37°C until the OD600 reached 1.0 and then induced with isopropyl-beta-D-thiogalactopyranoside (IPTG) at a lower temperature of 21°C. After the cells were harvested, sonicated and purified on Ni-NTA Superflow (Qiagen, Hilden, Germany), the His-tag was removed with biotinylated thrombin (Novagen) and further purified on the Superdex 200 10/30 column (GE Healthcare Biosciences, Uppsala, Sweden). Protein was stored at −80°C in a 20 mM potassium phosphate buffer (pH 7.3) supplemented with 150 mM NaCl, 0.5 mM Tris-2-carboxyethyl phosphine (TCEP) and 10 % glycerol.
Recombinant TPMT enzyme activity measurements
The enzyme activity of recombinant TPMT was measured with 84 μM 6-MP as substrate at room temperature using a spectrophotometric method (Hitachi-U-2800 spectrophotometer; Hitachi,Tokyo, Japan) [13] . The decrease in absorbance was monitored at 320 nm for 30 min using a TPMT protein concentration of 1 μM, 1 mM SAM and 200 μM MTX in 20 mM potassium phosphate (pH 7.3), 75 mM NaCl, 2 % glycerol, 0.5 mM TCEP. The enzyme activity was expressed as a percentage of the activity measured on TPMT protein incubated with CV.
Fluorescence measurements
To determine the binding constant of MTX to TPMT, MTX was titrated at concentrations between 0 to 250 μM. Aliquots of 1 μl MTX from a stock solution of 10 mM MTX dissolved in 0.1 M NaOH were added to 1 μM TPMT protein in 20 mM potassium phosphate (pH 7.3), 75 mM NaCl, 2 % glycerol, and 0.5 mM TCEP. Fluorescence measurements were performed at 21°C with the excitation wavelength of 295 nm specific for tryptophan residues, and emission spectra were recorded at 310-550 nm (Fluoromax-4; Horiba, Kyoto, Japan). The maximum intensity of the fluorescence emitted by the tryptophan residues obtained at 340 nm was plotted against the increased concentration of MTX.
Statistical analysis
Statistical analysis was conducted using SPSS ver. 19.0 (SPSS, Chicago, IL) and Prism software ver. 5.01 (GraphPad, San Diego, CA). For the cell line experiments, parametric statistics were used [mean and standard error of the mean (SEM)], and differences between cell treatments were analysed using Student's t test. For analysis of variables among patients, non-parametric statistics were used [median and interquartile range (IQR)], and the Wilcoxon's test was used to compare groups. A p value of <0.05 was considered significant.
Results
A total of 53 children with T-cell or pre-B ALL ages of 7.5± 4.6 (range 1-17) years were included in this study (Table 1) and followed the NOPHO ALL-2000 treatment protocol. The majority (81 %) were treated according to the standard and intermediate intensity protocols, whereas 11.3 % were treated with the intensive protocol, 3.8 % with the very intensive protocol and 3.8 % with the extra intensive protocol. Forty-nine children (92.5 %) were genotyped as TPMT*1/*1 and 7.6 % as heterozygous for one nonfunctional TPMT allele. None of the 53 children were TPMT deficient (TPMT <2.5 U/ml pRBC) or carried two non-functional alleles. Samples of two of the wildtype patients were only available at diagnosis and not for the follow-up.
TPMT enzyme activity during treatment
The median TPMT enzyme activity upon diagnosis was 9.5 (IQR 7.8-10.9) U/ml pRBC for TPMT wild-types (n=47) and 4.7 (IQR 4.6-5.2) U/ml pRBC for TPMT heterozygous individuals (n=4). Of individuals with the TPMT genotype TPMT*1/*1, 40 % had an initial enzyme activity at diagnosis below the cut-off for normal activity (9 U/ml pRBC). All four heterozygous individuals (TPMT*1/*3A or TPMT*1/*3C) had an initial enzyme activity of <9 U/ml pRBC. TPMT enzyme activity was measured at six different points in time from diagnosis up until 24 months after the end of maintenance therapy. The TPMT enzyme activity in wild-type individuals increased significantly and reached its highest value on day 106 (median TPMT 14.9 vs. 9.5 U/ml pRBC at diagnosis; p=0.001) (Fig. 1) . The four individuals heterozygous for TPMT also showed an increase in TPMT enzyme activity during the first 3 months (median TPMT 8.3 vs. 4.7 U/ml pRBC), although not statistically significant. The TPMT enzyme activity seemed to stabilise during the maintenance treatment (Fig. 1) .
In vivo effect of MTX on TPMT and 6-MP metabolites Samples were obtained at the time of HD-MTX infusions from those patients when sufficient blood was available for research purposes. TPMT analysis was prioritised over metabolite measurements when a sufficient amount of blood was not available for both assays. During the time period prior to infusion of HD-MTX and until 66 h later (66 h post-fusion), the TPMT levels decreased by 9.2 % (IQR −13 to+0.65 %; n=21, p=0.013), whereas the meTIMP levels did not change and the TGN levels decreased by 18 % (−26 to −15 %; n=15, p=0.006) ( Table 3 ). The median MTX plasma concentration 23 h following the start of MTX infusion was 84 μM (IQR 57-102 μM; n=19).
In vitro effect of MTX on TPMT enzyme activity in MOLT4 cells
The TPMT enzyme activity in MOLT4 cells showed an initial increase after 24 h of incubation with 90 μM MTX. However, a significant decrease to 26 % of the activity of the CV was observed after 48 h, and the enzyme activity was only 1.8 % after 72 h (Fig. 3) . The CV did not affect TPMT enzyme activity, as shown from comparisons with untreated MOLT4 cells in Fig. 2 . The hydrophobic active site of TPMT (Fig. 3a) harbours three out of the five tryptophans in the structure of TPMT (Fig. 3b) . To determine whether MTX is a potential ligand to TPMT, we determined tryptophan fluorescence (with titration of MTX to TPMT). Figure 4 shows that the binding profile of MTX to TPMT; a K d (dissociation constant) of approximately 24 μM could be determined. The remaining enzyme activity of the recombinant wild-type TPMT protein after incubation was 16 % with 200 μM MTX.
Discussion
The results of this study show that TPMT enzyme activity fluctuated from time of diagnosis throughout the time of treatment. At the time of diagnosis, 40 % of wild-type TPMT ALL patients displayed a deceptively low TPMT enzyme activity according to genotype (Fig. 1) . TPMT heterozygous individuals had a TPMT enzyme activity within the range of our reference values (2.5-8.9 U/ml pRBC). In wild-type TPMT ALL patients, TPMT enzyme activity increased from the start of treatment up to at least postinfusion day 106, when all TPMT wild-type individuals showed a TPMT enzyme activity of >9 U/ml pRBC. Even though not specifically investigated in our study, RBCs do not constitute a homogenous group and they have a life span of 120 days. Lennard et al. showed that the RBC population at diagnosis was influenced by disturbed haematopoiesis and that the population consisted of an excess of old RBCs [14] . In that study, a density gradient centrifugation of the RBCs showed that the population corresponding to the older cells displayed a lower TPMT enzyme activity compared to newer cells. In our study, TPMT enzyme activity increased during the first 3 months following the initiation of treatment, in accordance with the theory that the increase in enzyme activity reflects the recovering haematopoiesis in the patients. However, other drugs could affect TPMT enzyme activity, although it is difficult to say what impact these drugs may have on the enzyme activity compared to the ages of the RBCs. RBC transfusion may also have an impact on TPMT activity, although Brouwer et al. showed that this effect was not significant in wild-type individuals receiving transfusions [15] . Determining TPMT enzyme activity at diagnosis may lead to a deceptively low TPMT value which could then lead to the risk of initially undertreating the patient, particularly if this result is used to determine the starting dose of 6-MP. It is preferable that TPMT genotyping is performed using techniques that allow for the detection of novel/rare variants; however, most laboratories only genotype for the three most common TPMT sequence variants. Our results are in accordance with a recently published paper in a large cohort of ALL patients in the UK [16] . Data are presented as the median with the interquartile range given in parenthesis TGN, Thioguanine nucleotides; meTIMP, methylthioinosine monophosphate; RBC, red blood cells a Normalised metabolite levels were calculated by dividing the metabolite levels with the daily 6-mercaptopurine (6-MP) dose 
In vivo and in vitro effects of MTX on TPMT and 6-MP metabolites
When we measured TPMT enzyme activity and TGN and meTIMP levels before and after HD-MTX infusions in children who were already on oral 6-MP treatment, we found a median decrease in TPMT enzyme activity of 9.2 % at 66 h after the start of MTX infusion (Table 3) . Despite this decrease in enzyme activity, we did not observe any effect on meTIMP levels at the same time point. We also observed decreased TGN levels, which is in accordance with results reported previously [17, 18] . Zaza et al. [18] investigated gene expression and TGN levels after the administration of high-and low-dose MTX infusions in leukemic blasts and showed that patients treated with 6-MP alone achieved higher TGN concentrations than those treated with the combination of 6-MP + MTX. Furthermore, there were distinct sets of upregulated genes in each treatment group [18] . We hypothesise that the interaction between the TPMT protein and MTX is prompt, although the effect of this inhibition on the metabolism in the context of TGN and meTIMP formation may be a phenomenon seen at a later time point. It is also possible that other mechanisms, such as those discussed above, will mask the effect of TPMT inhibition on drug metabolism. A study by de Beaumais et al., which aimed to examine metabolite levels during treatment, discovered that TGN levels were dependent on the TPMT genotype as well as the patient's age, whereas meTIMP levels were dependent on the TPMT and inosine triphosphate pyrophosphatase (ITPA) genotypes [19] . ITPase deficiency has been shown to be a risk factor for 6-MP toxicity [2] .
In our study, the metabolite levels were only measured prior to and on one occasion after the initial MTX infusion. The effect of ITPA genotype on metabolite levels during treatment was a subject deemed by the authors to be beyond the scope of this article.
To the knowledge of the authors, no study has yet investigated the interaction between 6-MP and MTX by focussing specifically on the influence of MTX on TPMT enzyme activity. The decrease in TPMT enzyme activity was intriguing, and by using recombinant TPMT, we were able to perform protein and biophysical characterisation studies of TPMT incubated with MTX in vitro. The hypothesis was that MTX was a potent ligand to TPMT due to effects on TPMT enzyme activity after HD-MTX infusions in children with ALL. The determined crystal structure of human TPMT [20] showed an active site (Fig. 3a) with a large hydrophobic cavity providing the potential for binding with purine analogues as well as with other hydrophobic compounds. Experiments in our laboratory have shown that, for example, the hydrophobic compound anilino-naphtalene sulfonate binds to TPMT with high affinity (data not shown). The protein sequence of TPMT contains five tryptophans, three of (Fig. 3b) . To investigate any potential binding, we used a fluorescence method to study the quenching of tryptophans following the addition of MTX. The titration of MTX to recombinant TPMT protein (Fig. 4) showed binding with an approximate K d of 24 μM. Taking into account that the median plasma MTX concentration 23 h after the initiation of MTX infusion was 84 μM, we conclude that MTX binds to TPMT at relevant physiological concentrations. We also investigated the effect of 90 μM MTX on TPMT enzyme activity after 24, 48 and 72 h of incubation in a leukemic cell line (MOLT4). During the first 24 h of incubation, we detected an increase in TPMT enzyme activity; however, after 48 h of incubation a significant decrease was found in enzyme activity compared to that of the CV (26 % of CV, p<0.001); this inhibition continued over time, and after 72 h the enzyme activity was almost undetectable. We cannot rule out the possibility that the decrease in TPMT activity partly reflected an antiproliferative effect of MTX, even though our activity measurements were always done using the same number of cells. It is not clear why the enzyme activity increased at the beginning of MTX incubation. Brouwer et al. [15] showed that TPMT enzyme activity increased in MOLT4 cells after incubation with MTX; however, in their study, cells were simultaneously treated with methionine, thus creating increased amounts of SAM in the cells. As SAM stabilises TPMT, the increase in enzyme activity observed by these authors may be attributable to SAM, not to MTX [21] .
Conclusion
In childhood ALL, the TPMT status should be determined by TPMT genotyping analysis. Genotyping is preferable as enzyme activity measurements during the first 106 days of treatment will lead to a misclassification which could potentially lead to initial underdosing of these patients. The preferred genotyping technique should allow for detection of novel variants. MTX binds to TPMT in vitro and inhibits TPMT enzyme activity both in vitro and in children with ALL after the initiation of HD-MTX infusion. Understanding the mechanisms of drug synergism as well as other causes for differences in drug response is important in order to improve treatment and decrease treatment-related toxicity.
